InnoCan Pharma Israel and Tel Aviv University tech-transfer company Ramot are collaborating to develop a new exosome-based technology that targets the Covid-19 coronavirus and other types of lung inflammation.

“CBD-loaded exosomes may hold the potential to provide a highly synergistic effect of anti-inflammatory properties and help in the recovery of infected lung cells,” the company announced.

“This product, which is expected to be administrated by inhalation, will be tested against a variety of lung infections.”

Exosomes are small particles created when stem cells are multiplied. Exosomes can act as “homing missiles,” targeting specific damaged organs and facilitating cell-to-cell communication.

When the cell-healing properties of the exosomes are combined with the anti-inflammatory properties of CBD, it is expected to reach high synergetic effect. The research results also may be beneficial to treatments for central nervous system indications such as epilepsy.

Under the terms of the research agreement, InnoCan and a team led by Prof. Daniel Offen, a leading researcher specializing in neuroscience and exosome technology at Tel Aviv University, will collaborate to develop the cell therapy product based on Prof. Offen’s work in the field.

InnoCan has agreed to fund the research based on agreed milestones, in the aggregate amount of approximately $450,000 for the first stage. The company recently closed a $5.1 million (Canadian) prospectus offering of units, which will help finance the research.